Entrada Therapeutics procures $116m Series B

Entrada Therapeutics Inc., a biotechnology company focused on treating devastating diseases using intracellular biologics, has secured $116 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this